Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 100 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules
C4161001
Phase 2 small_molecule active
Quick answer
Fulvestrant EVER Pharma 250 mg Injektionslösung in einer Fertigspritze, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 100 mg hard capsules, IBRANCE 125 mg hard capsules, IBRANCE 75 mg hard capsules for Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC and NSCLC) is a Phase 2 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Indication
- Breast Cancer, Ovarian Cancer, SCLC (Part 1 also had TNBC and NSCLC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active